The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
| العنوان: | The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease |
|---|---|
| المؤلفون: | Gavin C. Harewood, Aman Shah Afridi, Stephen E. Patchett, Neasa Mc Gettigan, Caroline Lardner, Danny Cheriyan, Grace Harkin, Aoibhlinn O'Toole, K Boland |
| المصدر: | International Journal of Colorectal Disease. 36:1231-1241 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Drug, medicine.medical_specialty, Crohn's disease, Combination therapy, business.industry, media_common.quotation_subject, Gastroenterology, Hepatology, medicine.disease, Inflammatory bowel disease, Ulcerative colitis, Infliximab, Discontinuation, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, business, media_common, medicine.drug |
| الوصف: | Secondary loss of response (LOR) to infliximab (IFX) commonly occurs. One cause is the development of anti-drug antibodies (ADAs). Evidence regarding the optimal management of ADAs is lacking. We aim to identify the best practice of management of ADAs to IFX to avoid discontinuation of therapy and to determine specific ADA cut-off values to determine pre-specified clinical outcomes. This is a 3-year study of patients receiving IFX who developed ADAs > 8μg/ml. We reviewed the management strategies and subsequent outcomes in patients who developed ADAs. A total of 132 patients are included. Baseline characteristics include 54% male patients and mean age of 39.4 years. Fifty-two percent (n = 69) of patients discontinued IFX following the development of ADAs, 33.3% (n = 44) sited as secondary to LOR. Both an increase in IFX and adjustments to combination therapy were associated with lower rates of discontinuation of IFX vs no intervention (p value 16μg/ml, AUC 0.642, p value 0.003), steroid use (ADA >19 μg/ml, AUC 0.61, p value 0.048) development of infusion reactions (ADA> 37 μg/ml, AUC 0.68, p value 0.045) and switch to another biologic (ADA >45 μg/ml, AUC 0.739, p value |
| تدمد: | 1432-1262 0179-1958 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::1e62198878804e6a66c339b6fd427e1e https://doi.org/10.1007/s00384-021-03855-4 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........1e62198878804e6a66c339b6fd427e1e |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14321262 01791958 |
|---|